Please enter a search term.
Posted: Jan 10, 2022 / 01:55 PM EST
Updated: Jan 10, 2022 / 01:55 PM EST
“The following is sponsored content from Amgen”
For the roughly 1 in 8 U.S. patients with non-small cell lung cancer 2, knowing their biomarker status could unlock the door to a newly approved treatment.
FOR MORE INFORMATION: lumakras.com